Codexis, Inc. (CDXS) shares are gaining more than 23 percent on Friday morning trade, continuing an uptrend since the company revealed an amendment and extension of an agreement with Merck to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin. There were no corporate announcements on the day to impact the stock movement.

Create Account

Dark

chart

exchange

Check out our Level2View

Codexis, Inc. (CDXS) shares are gaining more than 23 percent on Friday morning trade, continuing an uptrend since the company revealed an amendment and extension of an agreement with Merck to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin. There were no corporate announcements on the day to impact the stock movement.

RTTNews | Oct 1, 2021 10:01AM EDT

10:01 Friday, October 1, 2021 (RTTNews.com) - Codexis, Inc. (CDXS) shares are gaining more than 23 percent on Friday morning trade, continuing an uptrend since the company revealed an amendment and extension of an agreement with Merck to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin. There were no corporate announcements on the day to impact the stock movement.

Currently, shares are at $26.81, up 15.26 percent from the previous close of $23.26 on a volume of 1,370,044. For the 52-week period, the shares have traded in a range of $11.60-$30.45 on average volume of 316,984.

Read the original article on RTTNews ( https://www.rttnews.com/3229924/codexis-uptick-continues.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved